Clinical Trial Search

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Number of Participants Requiring Mechanical Ventilation or Dying — 3; 3 Participants

Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free

Primary: Body Temperature — 98.1 degrees Fahrenheit

Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds

Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants

Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days

Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…

Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants

Primary: Number of Participants With Problems in Their Health Care Due to COVID-19 Related Isolation — 155 Participants

Primary: APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) — 8.7; 8.6 Score on a scale — p=0.467

Primary: Measuring the Change in Inflammation — 23.23; 34.82 mg/L — p=0.01

Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…

Primary: Change From Baseline to Day 8 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Shedding — -2.88; -3.52; -3.75; -3.03 log10 copies/ml — p=0.4829

Primary: Percent Change in D-dimer — -5.6; -2.4 percent daily change — p=0.24

Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days

Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person

Primary: Level of BP in mm Hg — 136; 138; 34; 82 mm Hg

Primary: Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 — 85.7; 87.5; 74.4 percentage of participants — p=0.2598

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…

Primary: Percentage of Participants Alive and Without Respiratory Failure Through Day 28 — 86.4; 79.2 percentage of participants — p==0.599

Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale

Primary: Safety of Clazakizumab for the Treatment of Patients With COVID-19 Disease — 3; 3; 6; 8 Adverse Events — p=0.10

Primary: Androgenetic Alopecia Frequency in Participants. — 209; 37; 11; 43 Participants